Supernus Pharmaceuticals (NASDAQ:SUPN) Receives Hold (C) Rating from Weiss Ratings

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “hold (c)” rating reaffirmed by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently weighed in on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 30th. Piper Sandler upped their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a report on Friday, August 29th. Finally, Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.50.

Supernus Pharmaceuticals Stock Down 0.1%

SUPN stock opened at $48.00 on Wednesday. The company has a market cap of $2.69 billion, a P/E ratio of 41.74 and a beta of 0.78. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $49.66. The business has a fifty day moving average of $44.40 and a 200-day moving average of $36.44.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CFO Timothy C. Dec sold 11,780 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the completion of the sale, the chief financial officer directly owned 1,246 shares in the company, valued at $55,434.54. This represents a 90.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jack A. Khattar sold 10,235 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $48.02, for a total value of $491,484.70. Following the transaction, the chief executive officer directly owned 1,144,336 shares of the company’s stock, valued at $54,951,014.72. This represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 302,841 shares of company stock valued at $13,361,449 over the last ninety days. 8.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SUPN. GAMMA Investing LLC boosted its position in shares of Supernus Pharmaceuticals by 4,005.4% during the first quarter. GAMMA Investing LLC now owns 43,230 shares of the specialty pharmaceutical company’s stock worth $1,320,000 after buying an additional 42,177 shares during the period. SG Americas Securities LLC boosted its position in shares of Supernus Pharmaceuticals by 63.6% during the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company’s stock worth $579,000 after buying an additional 6,867 shares during the period. Azzad Asset Management Inc. ADV acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $552,000. Exchange Traded Concepts LLC boosted its position in shares of Supernus Pharmaceuticals by 12.5% during the first quarter. Exchange Traded Concepts LLC now owns 24,881 shares of the specialty pharmaceutical company’s stock worth $815,000 after buying an additional 2,762 shares during the period. Finally, QRG Capital Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 5.5% during the first quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company’s stock worth $576,000 after buying an additional 913 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.